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ABSTRACT 
Deep Vein Thrombosis is a clotting disorder that usually leads to the formation 
of clots in veins deep within the legs. Deep Vein Thrombosis generally leads to 
a life threatening condition called pulmonary embolism where the clot breaks 
away and blocks the arteries of lungs. DVT affects about 600,000 people in 
United States and causes approximately 300,000 deaths per year. Traditional 
DVT treatments have relied on using anticoagulants to prevent the recurrence 
of DVT but not in its treatment. Here we have developed a minimally invasive 
model that uses low-powered ultrasound as a therapeutic aid. We have used 
the principles of time-reversal acoustics to develop an ultrasound modality that 
thrombolyses the clot without the aid of any thrombolytic. We hypothesize that 
this modality would aid in the development of a treatment methodology that 
would reduce the dosage of thrombolytics and anti-coagulants without 
reducing the efficacy of treating the thrombus. 
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Chapter 1 
1.   Deep Vein Thrombosis 
Deep Vein Thrombosis (DVT) refers to abnormally coagulated blood in one of the deep 
veins of the leg (Figure 1.1) or the arm.  It commonly results in valvular dysfunction and 
chronic swelling.  Untreated thrombus often gets fragmented leading to fatal pulmonary 
embolism (PE) [6] (Figure 1.2). 
 
 
Figure 1.1: (Left) Venous thrombus formation in the cusp of veins [Image source: Thrombosis adviser – 
Bayer Pharma AG
 7
]
 
(Right) Venous thrombus [Image source: Patel et al.
6
] 
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Figure 1.2: A pulmonary embolus [Image source: Patel et al.
6
] 
 
Rudolf Virchow described 3 factors popularly known as the Virchow’s triad that 
contribute to venous thrombosis. These factors are 1) Venous stasis 2) Activation of 
coagulation and 3) Vein Damage 
 
The obstruction or slowing of venous blood also known as venous stasis results in an 
increase in viscosity and leads to the formation of microthrombi. The microthrombi grow 
larger and obstruct blood flow. Activation of coagulation or development of a 
hypercoagulable state occurs due to a biochemical imbalance resulting from an 
increase in tissue activating factor or decrease in plasma antithrombin. Vein damage 
which is endothelial may be intrinsic or can occur from external trauma. All these factors 
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generally result in the development of an early thrombus that interacts with endothelium. 
This causes local cytokine production, leukocyte adhesion leading to abnormal clotting 
or thrombus production. These factors cause an imbalance between the coagulation 
cascade and fibrinolysis leading to the propagation of thrombus [6]. 
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1.1 Haemostasis and Fibrinolysis 
1.1.1 Coagulation 
 
In a normal healthy individual blood flows as a liquid. However in the event of an injury 
to any vessel a complex pathway is initiated that leads to the recruitment of blood 
platelets and fibrin to form a blood clot thereby stopping the blood flow [8, 9]. This 
phenomenon of stopping the blood flow or hemorrhage is called hemostasis. This 
process generally involves vasoconstriction, platelet response and coagulation [10, 12]. 
On subsequent repair of the damaged blood vessel, the clot is dissolved by a process 
called fibrinolysis [8]. The process of vasoconstriction and platelet response, followed by 
coagulation and fibrinolysis are sometimes referred to as primary, secondary and 
tertiary hemostasis respectively [12]. 
 
In the event of an injury to the blood vessel there is a reflex contraction of circular layers 
of smooth muscle surrounding the endothelium thus causing vasoconstriction. 
Vasoconstriction reduces the extravascular blood flow as well as the local blood flow 
[12, 13].  Immediately thereafter there is a platelet response which leads to the 
recruitment of platelets at the site of injury. The platelets adhere to the exposed sub 
endothelial collagen at the site of injury. In areas of high flows, the glycoprotein 1b-IX 
receptors on the platelets bind to the sub endothelial collagen through the von 
Willebrand factor (vWF) [11-13]. In areas of low flow the platelets will adhere to collagen 
and fibronectin [13]. The binding causes the platelets to change shape activating a 
collagen receptor called glycoprotein IIb/IIIa [12]. Subsequently they release a number 
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of chemical factors prominent of which are thromboxane A2, serotonin and adenosine-
di-phosphate (ADP) [10-13]. The release of these factors further augments the 
vasoconstriction, makes the platelets sticky and clumps them together. This step 
subsequently leads to the initiation of the clotting cascade [10].  The platelet 
aggregation is further enhanced through the production of thrombin by the coagulation 
cascade. The aggregation is mediated and stabilized by fibrinogen which binds to 
glycoprotein IIb/IIIa leading to the formation of primary platelet plug [12].   
 
 
Figure 1.3: An overview of steps in hemostasis [Image source: Casey G et al.
3
]  
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The next stage of hemostasis is the initiation of coagulation of blood through a) the 
extrinsic or tissue factor pathway and b) the intrinsic pathway. Though it was earlier 
believed that both the pathways are equally involved in the initiation and propagation of 
coagulation cascade it has now been realized that the extrinsic pathway plays a more 
significant role [8]. 
 
Figure 1.4: Initiation of coagulation cascade by the intrinsic and extrinsic pathways [Image source: Norris et 
al.
8
].   
 
Extrinsic pathway  
Extrinsic pathway or the tissue factor pathway is the predominant blood coagulation 
pathway that is triggered when a membrane bound protein called tissue factor (TF) 
comes into contact with a factor called VII (VIIa is the activated form) present in the 
7 
 
plasma [1,4]. Cells (sub endothelial pericytes and fibroblasts) [4] express TF in the 
event of a vascular injury and come into contact with factor VII, a serine protease. The 
contact mediates the conversion of factor VII to its activated form VIIa. Cells like the 
monocytes and smooth muscle cells are also triggered to produce TF by cytokines 
produced in the event of an injury. This event leads to the formation of a TF-VIIa 
complex which initiates a signaling cascade as shown in Figure 1.4. The TF-VIIa 
activates factor IX to IXa and X to Xa. The TF mediated extrinsic pathway is regulated 
by two inhibitors- the Tissue Factor Pathway Inhibitor (TFPI) that blocks the TF-VIIa 
activation of factor X and anti-thrombin which inhibits thrombin and factor Xa. Thus only 
when TF is exposed at a high concentration to overcome the inhibition by TFPI and anti-
thrombin does the coagulant cascade proceed forward through the extrinsic pathway 
[8]. 
 
Intrinsic pathway  
In the intrinsic pathway auto-activation of a factor XII to XIIa takes places through 
binding to a negatively charged surface [8]. Factor XIIa subsequently causes the 
conversion of prekallikrein to kallikrien and of factor XI to XIa [8,14]. Simultaneously 
cleavage of high-molecular weight kininogen (HMWK) also occurs to produce HMWKa. 
These changes subsequently cause the activation of factor IX to IXa.  Defects in factor 
XI are associated with improper fibrinolysis and thrombosis [8]. 
 
Factor IX activated through the intrinsic or extrinsic pathway leads to the formation of a 
complex called tenase complex [8]. Factor IXa forms the tenase complex with factor 
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VIIIa, calcium and phospholipids and thereby activates factor X to Xa. von Willebrand 
factor(vWF) binds to the platelets and activates factor VIII to VIIIa [15]. Thrombin can 
also activate factor VIII [9]. The activated factor Xa participates in the formation of a 
prothrombinase complex which consists of factor Xa, factor Va (activated through 
anionic phospholipids or thrombin) and a phospholipid membrane surface. This leads to 
the conversion of prothrombin to α-thrombin, a serine protease. The conversion of 
prothrombin to thrombin occurs through an intermediate called meizothrombin. 
Miezothrombin formed by the cleavage at Arg 320 [8] which if further cleaved at Arg 271 
produces α-thrombin and prothrombin fragment I.2 [8 ,17]. 
 
 
 
Figure 1.5: Secondary structure of thrombin (PDB ID: 1MKX) represented as a cartoon. The above structure 
contains two molecules of thrombin. The one on left is an inactive form of thrombin and the one on right is 
the corresponding active form. The inactive form is cleaved into the active form exposing serine residue 
which can cleave fibrinogen to form fibrin
78
. 
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The activated thrombin plays many roles in hemostasis. It is responsible for the 
formation of fibrin from fibrinogen, activation of platelets, coagulation factors and 
activation of inhibitors like protein C and thrombin activatable fibrinolysis inhibitor (TAFI) 
[8 ,18].  The activated thrombin converts soluble fibrinogen to an insoluble fibrin 
polymer. This forms a clot that plugs the site of the injury and leads to wound healing. A 
number of regulatory mechanisms are in place to ensure that the clotting takes place 
only at the site of injury and that no inadvertent activation of clotting takes place.  The 
heparin-antithrombin III (ATIII), protein C and thrombomodulin protein S and tissue 
factor inhibition pathways are the natural anti-coagulant mechanisms.   
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1.1.2 Fibrinolysis 
 
The fibrinolytic system is an enzymatic system that is responsible for dissolution of fibrin 
clots in the blood vessels [8, 19, 20]. The system comprises of a proenzyme called 
plasminogen, which is converted to an active form called plasmin by different 
plasminogen activators (PA’s). The two prominent plasminogen activators are tissue-
type plasminogen activator (t-PA found in tissues) and urokinase-type plasminogen 
activator (u-PA).  
 
Figure 1.6: Fibrinolysis Overview-Cleavage of single chain tissue plasminogen activator (sc-tPA) and single 
chain urokinase plasminogen activator (sc-uPA) by plasmin to two chain tissue plasminogen activator (tc-
tPA) and two chain urokinase plasminogen activator tc-uPA. Activation of plasminogen to plasmin by tc-tPA 
and tc-uPA. Subsequent cleavage of fibrin by plasmin [20].PAI =Plasminogen activator Inhibitor that inhibits 
activation of plasminogen by binding to tc-tPA and tc-uPA; α2-PI=α2-plasmin inhibitor, α2-MG = α2 
microglobulin inhibit plasmin [Image source: Cesarman-Maus Gabriela et al.
20
] 
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The physiologic PA’s activate plasminogen at the surface of fibrin. Activation of 
plasminogen in plasma occurs by the cleavage of an Arg-Val bond. The cleaved 
plasminogen contains lysine binding sites that interact with lysine and 6-amino hexanoic 
acid. These sites mediate specific binding of plasminogen to fibrin and the interaction of 
fibrin with α2-antiplasmin and play an important role in fibrinolysis. Fibrin bound plasmin 
(protected from α2-antiplasmin) degrades the fibrin of the thrombus. The physiologic 
PA’s - t-PA and u-PA activate the plasminogen in different ways. t-PA is a serine 
protease with a single polypeptide chain containing 135 amino acids. t-PA is activated in 
presence of fibrin where plasminogen and fibrin are sequentially adsorbed onto fibrin 
creating a ternary complex.  The high affinity of t-PA for plasminogen in presence of 
fibrin converts plasminogen to its active form called plasmin which degrades fibrin.  
Urokinase initially exists as a single chain pro-urokinase (scu-PA). Upon hydrolysis by 
plasmin it is converted to a two chain urokinase (tcu-PA). The activated tcu-PA thereby 
activates fibrin bound plasminogen which subsequently degrades fibrin. Fibrinolytic 
system is inhibited primarily by α2-antiplasmin and plasminogen activator inhibitor 
respectively. α2-antiplasmin is the primary physiologic inhibitor of plasmin in blood 
plasma whereas plasminogen activator inhibitor-1 (PAI-1) inhibits the physiologic 
plasminogen activators t-PA and u-PA. Thrombin bound to thrombomodulin activates 
thrombin-activatable fibrinolysis inhibitor (TAFI) which reduces plasmin activity by 
making fibrin more resistant to t-PA mediated fibrinolysis [20, 22].  
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1.2 Disruption of hemostatic equilibrium and thrombosis 
 
 
Figure 1.7: The balance between thrombus formation and degradation is carefully regulated by several 
factors. Coagulation and fibrinolysis are linked through thrombin, thrombomodulin and thrombin-activatable 
factor inhibitor [Image source: Nesheim et al.
22
] 
 
The thrombus formation and fibrinolysis are in equilibrium and occur continuously at a 
microscopic level. Regulation of coagulation is important to prevent formation of 
massive thrombi. In order to do so a number of regulatory mechanisms are in place. 
Further coagulation takes place only on the surface of activated cells and platelets. 
Tissue factor pathway inhibitor (TFPI) and anti-thrombin are important proteins 
regulating coagulation. However it is the protein C anticoagulant pathway which is 
believed to play an important role in preventing coagulation at microscopic level.  
Thrombin bound to thrombomodulin activates protein C (APC) and forms a complex 
with protein S. The protein S-APC complex inactivates both factor Va and factor VIIIa 
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thereby inhibiting prothrombinase and tenase activity [8, 75]. In cases of APC resistance 
a mutation called Leiden mutation occurs on factor V where in Arg 506 is replaced by 
glutamine. Inactivation of factor V that generally occurs through cleavage at Arg 506 
and Arg 306 is now inefficient due to this mutation thereby conferring an inherited risk 
towards thrombosis. APC resistance is believed to be the most common inherited risk of 
thrombosis [8]. Anti-thrombin III deficiency is another major inherited disorder that leads 
to recurrent VTE [76]. Apart from these, mutations in protein C, protein S, endothelial 
protein C receptor (EPCR) seem to impart risk towards thrombosis [8]. 
Apart from genetic factors injury, stasis and other procoagulant factors disturb 
thrombosis-fibrinolysis balance and lead to a macroscopic thrombus that is obstructive 
in nature. In cases of trauma or surgery the level of anti-thrombin III (AT III) is 
decreased (especially in total hip replacement when the levels to a very low extent) 
increasing the chances of coagulation. The thrombus formation usually takes place 
behind valve cusps or at venous branch points [7]. According to certain studies low flow 
sites carry the greatest risk for development of venous thrombi [25, 26].  The thrombus 
incorporates inflammatory cells into the clot resulting in fibroelastic intimal thickening at 
the site of thrombus [27] leading to valvular dysfunction and overall vein thrombosis. 
Most of the patients who have experienced acute DVT experience venous stasis, 
valvular reflux and chronic edema [28]. Chronic venous insufficiency develops in 29-
79% of patients with an acute DVT [7, 30, 31]. Natural healing process is another 
mechanism that contributes to venous insufficiency. Inflammatory reaction and 
fibrinolysis break down the thrombus in the process altering the valves and venous 
walls. This process predisposes the damaged, incompetent, underlying valves to 
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venous reflux. The inflammatory reaction breaks down the collagen and elastin making 
the venous wall noncompliant [8, 33-38]. Incomplete removal of an obstructive thrombus 
with venous damage perpetuates venous insufficiency eventually leading to post 
thrombotic syndrome. 
Venous thrombi also break off from their location and travel to through the right heart to 
pulmonary artery causing ventilation perfusion defect and cardiac strain leading to 
pulmonary embolism (PE). PE occurs in 10% of patients with acute DVT and results 
upto 10% of hospital deaths [7, 27, 28]. 
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Chapter 2  
2. Treatment Strategies for Deep Vein Thrombosis 
 
Deep Vein Thrombosis (DVT) and the subsequent Post Thrombotic Syndrome (PTS) 
pose a major health hazard in most parts of the world. Venous thromboembolism (VTE) 
which encompasses DVT and pulmonary embolism (PE) affects more than 600,000 
people per year and causes 300,000 deaths per year in the United States. In the 
European Union the incidence is higher at over one million resulting in 500,000 deaths 
per year [1-3].  Approximately 250,000-300,000 cases of VTE in the United States have 
a first incidence of Deep Vein Thrombosis [3, 4].   DVT affects about 25% of patients 
undergoing all major surgical procedures with a mortality rate of about 12% [4].The 
recurrence of DVT after a non-surgical first incidence is about 18% in first 2 years and 
30% in 8 years.  Nearly 20-50% of patients develop post thrombotic syndrome after the 
incidence of DVT in the first two years [2, 5]. 
 
The need to prevent PE and PTS has brought forth a DVT management strategy rooted 
in the view of the disease as a condition that leads to pulmonary embolism and 
recurrent venous thromboembolism [6, 40]. This notion has primarily led to a treatment 
methodology that focused on the use of anticoagulant drugs to prevent recurrence of 
DVT.  
 
Also at a physiological level it has been well established that hypercoagulability, stasis 
of blood flow and venous endothelial injury (Virchow’s triad) are the major factors 
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responsible for incidence of DVT.  However at the molecular level it is influenced by 
interaction between various genes, inflammation, lipid biology and other incompletely 
characterized factors.  Owing to this incomplete characterization and the view that the 
disease is more a condition that leads to PE and recurrent VTE, conventional DVT 
treatment has primarily relied on the use of anticoagulants to prevent thrombus 
formation [40].  
 
 
Figure 2.1: Targets of anticoagulant drugs in the coagulant cascade [Image source: Brenner et al.
1
]. Direct 
factor Xa inhibitors (in pink) like rivaroxaban, apixaban, edoxaban, fondaparinux and YM150 act on Factor 
Xa. Dabigataran etexilate is a thrombin inhibitor (in blue). UFH (grey) and anti-thrombin (cyan) inhibit 
thrombin, factor XIIa, factor Xa, factor IXa, factor VIIa. VKA like warfarin used in long term anticoagulation 
inhibits factors II, VII, IX and X. 
 
The initial treatment involves the use of anticoagulant drugs like unfractionated heparin 
(UFH), low molecular weight heparin (LMWH) or pentasaccharide fondaparinux followed 
by the long term use of Vitamin K antagonist (VKA) such as warfarin. Generally UFH, 
LMWH or fondaparinux are given for 5 days subcutaneously and then discontinued if 
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the International Normalized Ratio (INR) is 2.0 or above for more than 24 hours [1, 51].  
Subsequently VKA is administered for 3 months or more based on risk of bleeding and 
INR values.  Randomized trials have shown that anticoagulant treatment with UFH and 
LMWH has a risk of recurrent DVT 4%, bleeding 3% and PE 2% [52, 53]. 
 
An anti-coagulant based treatment though effective has several issues associated with 
it, apart from the risk of excessive bleeding (approximately 2% have major bleeding in 
first three months and 1-3% thereafter with a fatality rate of 13% [54]). UFH also binds 
to plasma proteins and cells and is known to cause heparin-induced thrombocytopenia 
and osteoporosis. Heparin-immunoglobulin G complexes are formed that bind to Fc 
receptors on platelets, activating them.  These are removed during circulation causing 
thrombocytopenia. This process also generates platelet-derived microparticles which 
have procoagulant activity [1].  
 
Several studies have shown that anticoagulant treatment is not efficient in preventing 
the patients from developing post thrombotic syndrome (PTS) [39, 40, 43, 44]. 75% of 
patients with symptomatic DVT develop PTS in 5-10 years when using anticoagulation 
treatment alone [64, 65]. Anticoagulants usually do not completely resolve a thrombus. 
At a molecular level the factors behind the development of PTS are still not clearly 
understood. Inflammatory and growth factor mediators, extracellular matrix-derived 
factors, blood-borne elements are some of the factors that increase the thickness of the 
cell wall and reduce the compliance, thus promoting the development of PTS [40]. 
Though PTS at the microscopic level is not completely understood, at the macroscopic 
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level it has been proved that incomplete resolution of thrombus after the incidence of 
DVT leads to PTS [4, 39, 40, 44]. The presence of thrombus after DVT leads to PTS 
through obstruction and inflammation. The thrombus physically blocks the venous 
blood. Subsequently there is an inflammatory response to this thrombosis that directly 
damages the venous valves, alters the adjacent vein wall and leads to valvular reflux. 
Distal deep veins also dilate and become incompetent. Obstruction and the resulting 
valvular reflux cause ambulatory venous hypertension which in turn leads to edema, 
tissue hypoxia, injury, progressive calf dysfunction, subcutaneous fibrosis and skin 
ulceration [40].  Thus it is extremely essential for the early and efficient removal of the 
thrombus to prevent PTS and ensure long term healthy venous function [39]. Systemic 
embolism, chronic venous insufficiency, soft tissue ischemia and non-oral administration 
are other issues associated with anti-coagulant treatment [6]. 
 
With all these drugs (especially long term use of VKA) there is a substantial risk of 
bleeding which varies from patient to patient.  Several new generation anticoagulants 
are being developed that can be administered orally like rivaroxaban, apixaban, 
edoxaban and YM150 which are direct factor Xa inhibitors, dabigataran etexilate a 
direct thrombin inhibitor. Though the new-generation anti-coagulants show promise of 
reducing the risk of recurrent VTE they still are in clinical phase and show some new 
disadvantages.  A major limitation in the use of these drugs is the lack of any specific 
compounds that reverse the anti-coagulant effect. Also at times the oral route of 
administration is a problem in patients who have undergone major surgery. The effects 
of these medications have not been studied in patients with heart disease, cancer, and 
19 
 
in patients who have undergone valvular replacement etc.  These anticoagulants being 
small molecules also cross the placental barrier and hence cannot be used during 
pregnancy [1].  
 
Systemic/pharmacologic thrombolysis is a treatment strategy where the thrombus is 
dissolved using a fibrinolytic drug given via an intravenous line distant from the affected 
limb [40]. Streptokinase has been a popular first generation fibrinolytic drug that was 
proved to be more effective in addressing VTE than anticoagulants like heparin [40]. 
However the bleeding complications are much more frequent and more intensive when 
compared to anti-coagulant treatment. Hence the drug is not used in the current 
practice.  Recombinant tissue plasminogen activator (rt-PA) is a drug with greater 
fibrinolytic activity than other fibrinolytic agents and is currently the preferred drug 
systemic thrombolysis [40]. However studies have shown that the systemic 
administration route is not the best possible administration route to attain therapeutic 
drug concentration to lyse the clots. It was also observed that this administration route 
leads to extracranial bleeding [40]. Intracranial bleeding has also been noted with the 
use of fibrinolytic drugs with death and impairment as infrequent effects [6]. 
 
The advent of non-invasive vascular imaging using Duplex ultrasound and helical CT 
scanning, ultrasound facilitated catheter access into venous system, drug delivery 
through catheter systems facilitated the development of endovascular techniques to 
treat DVT [39,40]. Modern endovascular techniques to treat DVT consist of catheters to 
deliver drugs at the site of thrombosis, mechanical thrombectomy angioplasty and 
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stenting of venous obstructions [6]. Endovascular techniques aim to prevent PE, 
recurrent VTE and PTS and reduce drug dosage by enhancing concentration of the 
drug locally [6, 40]. 
 
Catheter direct thrombolysis (CDT) is a popular endovascular technique which uses a 
multiside hole catheter to dispense fibrinolytic drug at the site of thrombosis [40, 46, 47]. 
After the clot lysis underlying veins are evaluated by venography and any venous 
obstructive lesion identified is treated with balloon angioplasty or stent placement [40]. 
Some studies have shown that when compared to thrombectomy CDT treatment 
resulted in less residual thrombus, greater valvular competence, improved endothelial 
function [55] and also have been more effective than systemic thrombolysis [56,57]. A 
major limitation with CDT is the longer infusion times (1 to 3 days) to treat DVT. Studies 
have also reported extensive bleeding in certain cases (2%-3% of cases) using low 
doses of rt-PA [40, 48, 49, 50]. 
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Figure 2.2: A and B represent generation of rapidly flowing back-directed saline jets that flow back into the 
outflow channels from the tip of catheter. The high velocity creates a low pressure region and thus draws the 
thrombus into the catheter [Image source: Lin et al.
6
] 
 
Percutaneous mechanical thrombectomy is another method for thrombus removal that 
uses mechanical means to remove the thrombus. These methods are primarily used as 
an adjuvant to CDT or pharmacologic thrombolysis [6, 40, 45]. The combined treatment 
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methods are referred to as pharmacomechanical catheter directed thrombolysis or the 
PCDT and pharmacomechanical thrombectomy or the PMT. These methods promise 
reduced treatment times and removal of large thrombus volumes within a short period of 
time [40].  AngioJet system (Possis Medical, Minneapolis, MN) and the Trellis device 
(Bacchus Vascular, Santa Clara, CA) are two of the popular thrombectomy systems. 
The AngioJet system is based on Bernoulli’s principle where thrombus is drawn into 
catheter using backward flowing saline jets [4] (Figure 2.2). 
 
There are two general methods of PCDT application. One utilizes thrombectomy 
devices along with traditional CDT reducing the fibrinolytic drug dose and time of 
infusion [40, 58]. The other are the single session PCDT methods that rapidly disperse 
thrombolytic drug and remove the thrombus in a single 1-3 hour procedure [26,40,59,]. 
Major bleeds have been reported in 2-4% of the patients and symptomatic PE has been 
observed in cases where aggressive mechanical thrombectomy has been used [6]. 
However no conclusive studies have been performed that ascertain the efficacy and the 
safety of PCDT methods [40]. All patients undergo anticoagulant treatment irrespective 
of whether an endovascular procedure is performed [40]. 
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2.1 Ultrasound in thrombolysis 
Conte and de Lorenzi first showed the effect of ultrasound on biological tissue in 1940 
and in 1965 Anschuetz and colleagues used ultrasound for atherosclerotic plaque 
ablation [41, 62]. Rosenschein and colleagues first demonstrated the application of 
ultrasound to disrupt intravascular thrombi in 1990. They reported that the fibrin matrix 
was disrupted within the thrombi using ultrasound energy [4, 60,  61]. Subsequently 
over the last couple of decades ultrasound based thrombolysis has emerged as a 
promising endovascular alternative to treat DVT and as an adjunctive to 
pharmacological thrombolysis and anticoagulation treatment. US accelerated 
thrombolysis has low bleeding rates, enhanced clearance of thrombus with low 
treatment times. The drug dosage is low thereby this treatment reduces the bleeding 
complications [77].  
 
Ultrasound is believed to trigger fibrinolysis due to 1) acoustic cavitation 2) 
microstreaming 3) mechanical effects 4) intracellular microcurrents 5) thermal warming 
6) increased clot permeability. The mechanism of thrombolysis varies with the mode of 
delivery of ultrasound whereas the extent of lysis depends on the mode of delivery, 
acoustic parameters like frequencies used,  energy delivered, pulsed wave or a  
continuous wave, the depth of penetration,  magnitude of microstreaming, stability of 
cavitation, the thrombolytic drug used, microbubble agents used [4,41,62]. 
 
Currently ultrasound based thrombolysis technologies may be categorized into three 
categories – (1) intravascular catheter delivered external transducer ultrasound (2) 
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intravascular catheter-delivered transducer-tipped ultrasound (3) transcutaneous 
ultrasound [4, 41]. Intravascular catheter-delivered external transducer ultrasound uses 
an electrical generator that powers the ultrasound transducer which then transmits this 
ultrasound energy to a metal wire probe (of different lengths) causing a rapid motion in 
the surrounding fluid [41]. The rapid motion of the probe is said to cause acoustic 
cavitation, micro streaming and a mechanical perturbation thus initiating the fibrinolytic 
cascade. The range of frequencies are however limited to 19 KHz-50 KHz.  The 
transducer-tipped   ultrasound method utilizes a piezo electric element at the tip of the 
catheter which allows for frequencies to be delivered in the range of 0.1 MHz-2.0 MHz. 
The ultrasound intensity ranges from 0.6-2.0 W/cm2. At this intensity micro streaming is 
believed to play an important role in fibrinolysis with acoustic cavitation taking a minor 
role. The ultrasound delivered in this manner also aids in the increase of clot 
permeability and promotes clot lysis by enhancing the diffusion of fibrinolytic drug (into 
the clot (Eg. EKOS Endowave system) [4, 42, 77]. Both these methods are however 
invasive and limited by the size of the ultrasound transducer in the latter or probe wire in 
the former. The size of the probe wire and transducer restrict the frequencies that can 
be applied and place a limitation on the amount of ultrasound energy delivered to the 
site of lysis.  
 
Transcutaneous ultrasound thrombolysis is a non-invasive procedure that is readily 
used in patients with acute myocardial infarction or stroke [41]. Unlike transcatheter 
thrombolysis wherein the invasiveness causes time delay, logistic and technical issues 
during clinical implementation, this approach is faster and can be easily deployed. It is 
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believed that transcutaneous ultrasound enhances drug transport into the clot through 
micro streaming, acoustic cavitation and precavitation via the oscillation/vibration of 
micro bubbles [41, 63]. The major limitations of this system are the inability to focus 
ultrasound at a specific location, dissipation of energy through skin and other tissue, 
possible injury to the skin and tissue resulting from exposure to non-focused ultrasound 
and longer treatment time. The inability to focus also limits the delivery of therapeutic 
ultrasound at the desired location. 
 
Apart from thrombolysis, several applications of ultrasound in medicine require focused 
signal that is localized to a specific tissue. However various heterogeneities across 
different tissues, the interfaces and boundaries that affect the speed of the wave and 
absorption of energy, reflection, refraction and scattering across biological tissues 
greatly limit the focusing of external ultrasound energy.  Delivery of ultrasound energy 
using an internal transducer is invasive and carries the potential risk of causing internal 
damage.  The biggest disadvantage however is the transducer size which limits the 
amount of energy delivered, the frequencies applied and the delivery location. One of 
the goals of the current research is to overcome these limitations by using an ultrasound 
focusing methodology that is based on the principle of time-reversal acoustics. 
  
In the late 90’s Mathias Fink pioneered the concept of Time Reversal Acoustics (TRA) 
that allowed for focusing of ultrasound energy in highly inhomogeneous media. The 
method allowed for an acoustic signal to be focused spatially and temporally in a highly 
inhomogeneous media. TRA is based on the principle that in a non-dissipative 
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heterogeneous medium the wave equation is invariant. Thus for a given set of divergent 
waves that are reflected, refracted and scattered there exists a time-reversed version 
which retraces these exact paths and converges at the original source [68, 76]. The 
ability to focus in highly heterogeneous media helps localize ultrasound energy to a 
specific location and limits the exposure to other tissues. TRA focusing also allows for a  
 
 
Figure 2.3: A typical electro-magnetic signal received from the ‘beacon’ transducer [Image Source: US Patent 
7713200]. 
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Figure 2.4: A typical time-reversed ultrasound signal generated in response to the signal from the ‘beacon’ 
[Image Source: US Patent 7713200]. 
 
better spatial focusing that other focusing systems. The focal volume approaches the 
spherical diffraction limit. TRA focusing can also dictate the type of waveform (spherical 
or elliptical etc.) This helps in controlling the mechanism by which ultrasound can affect 
thrombolysis [70]. For any focusing of ultrasound using TRA an important requirement is 
the presence of an entity at the required location that provides necessary feedback.  
Generally a hydrophone or a highly reflective target is used as a beacon. The presence 
of such a beacon at the site often limits the TRA based focusing [70]. To overcome the 
above limitation the system contains a small piezo electric transducer at the tip of the 
catheter (which can be adjusted according to the vessel size) that is inserted into the 
clot. The piezo electric transducer acts as a beacon which pin points the location of clot. 
Thereafter external transducers using the principal of time-reversal acoustics focus the 
ultrasound energy at the beacon thereby greatly enhancing clot lysis. 
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Chapter 3 
3. Materials and Methods 
3.1 In vitro porcine clot preparation 
 
 
Figure 3.1: A typical porcine blood clot used for thrombolysis. The clot is enclosed in a silicone tube of 
diameter 1.2 centimeters approximately. The tube is clamped at both ends with plastic clamps as shown in 
the image. 
 
Accessing the carotid artery of the donating pig, approximately 15-20 ml of blood is 
collected in a silicone tube of inner diameter 1.2 centimeters with a clamp on one end. 
After filling the tube (with approximately 20ml of blood) the other end is clamped. The 
thrombus is allowed to form at room temperature for about 1hour.  Subsequently excess 
plasma is discarded and the clots are stored at approximately 5 °C.  The donating pigs 
were 15 weeks old and weighed 120lbs.  The blood was collected as per the regulations 
of Institutional Animal Care and Use Committee (IACUC) protocol. 12 tubes of clots 
were prepared according to this protocol.  
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To an additional set of 12 tubes, reconstituted thrombin (Sigma Aldrich) having a 
concentration of 100U/ml was added. Each tube containing 15-20ml of blood was mixed 
with approximately 0.75ml of reconstituted thrombin.  
 
3.2 Sensitivity calibration of ‘beacon’ transducer 
 
 
Figure 3.2: Schematic showing the setup for the calibration of beacon transducer. The hydrophone and the 
beacon transducer are placed at the same distance (Rayleigh distance) from the ultrasound transducer. Both 
of them lie in the same plane so that the acoustic pressure experienced by both is the same. The ultrasound 
transducer is connected to the function generator whereas the hydrophone and beacon are connected to a 
digital oscilloscope. 
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Figure 3.3: Experimental setup for calibrating the ‘beacon’ transducer. The pictures (L&R) depict the overall 
setup containing 1) ONDA low frequency hydrophone 2) Piezo Electric Ceramic Ring Transducer 3) Digital 
Oscilloscope 4) Function generator 5) Ultrasound ‘beacon’ transducer. These components are connected 
according to the schematic shown in Figure 3.2. 
 
A piezo electric ceramic ring transducer with resonant frequency of 190+/- 5 KHz (SMR 
2809t60118, STEMiNC- Steiner and Martins, Inc.) is placed within a glass beaker filled 
with water and is connected to a function generator. The ultrasound ‘beacon’ transducer 
and the low frequency hydrophone (ONDA HNR-1000 S/N: 1557) are placed at the 
Rayleigh distance (((OD2/ (4*λw)) where OD is outer diameter of the transducer and λw 
is wavelength of sound in water) of the ultrasound transducer (OD 28mm x ID 9mm x Th 
6mm). The setup ensures that the beacon and the transducer are in the same plane. 
2 
         3 
       4 
1 
  
 5 
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Thus the pressure experienced by the hydrophone and the beacon is the same. The low 
frequency hydrophone and the ultrasound beacon transducer are then connected to two 
different channels of the oscilloscope. A sine wave of frequency 342 KHz is applied and 
the corresponding peak-peak voltages are measured in both the channels. Since 
Sensitivity(S) * Pressure (P) = Voltage (V), we obtained the sensitivity of the beacon as 
1.0126e-6 V/Pa (given the sensitivity of hydrophone at 330 KHz is 0.56845e-6 V/Pa). 
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3.3 TRA based ultrasound thrombolysis 
 
Figure 3.4: Schematic showing the arrangement of various components for ultrasound assisted thrombolysis 
using Time Reversal Acoustics. The beacon is placed inside a reverberator. The reverberator is surrounded 
by external transducers which are connected to a power amplifier circuit which is powered both by an AC 
and DC source. The TRA electronics (powered by the AC source) is connected to the beacon transducer and 
the amplifier circuit. A computing interface controls the acoustic parameters based on signals received from 
TRA electronics.   
 
The beacon transducer (which also acts as a hydrophone) is placed within the 
cylindrical reverberator (made of ballistics gel) and connected to the TRA electronics 
through a female BNC connector.  The TRA electronics is connected to an AC power 
source and a computing interface. The computing interface contains the software that 
controls the various parameters associated with TRA focusing.  
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The cylindrical reverberator (Figures 3.5 and 3.6) is surrounded with transducers 
(temperature regulated at 25°C) that are in turn connected to a low impedance power 
amplifier circuit. The amplifier circuit is also connected to the TRA electronics.  A DC 
power source powers the computing interface housing the TRA software and the 
coolant fans of the amplifier circuit. The alternating power source provides the voltage 
across various circuit elements. 
 
The reverberator used in the given experimental setup is shown in the Figure 3.5. It is a 
ballistics gel based cylinder with an outer diameter of about 14 cm containing a narrow 
cylindrical channel of approximately 1.2 cm within which the clot to be thrombolysed is 
placed.  
 
Figure 3.5: A ballistics gel based cylindrical reverberator (Left) containing a UNI*FUSE catheter (cyan 
colored). Right (top) shows the initial position of the blood clot. Right (bottom) shows the blood clot in its 
final position in the reverberator with the catheter containing the ultrasound beacon transducer placed in it.  
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The clots are removed from the silicone tubes and placed in a petri dish for 
measurement. The weight of the clot is measured as per equation (1)   
Weight of clot [WC] = (Weight of petridish+ Weight of clot) [WP]-Weight of petridish 
containing residual blood [WR]            -         (1) 
 
The blood clot (approximately 1cm in diameter) is then placed in a broad cylindrical tube 
as shown above in Figure 3.5 (Top right). The tube is connected to the reverberator 
through a silicone tube (approximately 1.4 cm in diameter) that leads into a cylindrical 
channel within the reverberator (Bottom right). Using a pump (115V, 1.1A, 1phase) that 
drives water through this system, the blood clot is slowly driven into the final position in 
the cylindrical channel as shown in Figure 3.5 (Bottom left). Prior to placing the clot, the 
system of tubes and cylindrical channel is flushed with water to remove any air bubbles. 
A UNI*FUSE catheter (Angiodynamics Inc., Catheter size 5F) is inserted through the 
cylindrical channel so that it reaches the beginning of the clot. Subsequently the beacon 
transducer connected to the TRA electronics is inserted into the catheter such that the 
piezo electric element of the beacon transducer sits in the middle of the clot. 
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Figure 3.6: (Left) The reverberator with clot placed inside the narrow cylindrical channel within the 
reverberator. (Middle) The reverberator surrounded by ultrasound transducers. (Right) A close up of 
transducers placed around the reverberator containing the clot. The blue ultrasound gel is at the interface of 
reverberator and the transducers. 
 
After the clot is placed within the reverberator, 9 piezo electric ceramic ring transducers 
with resonant frequency of 190+/- 5 KHz (SMR 2809t60118, STEMiNC- Steiner and 
Martins, Inc.) are placed around the reverberator (shown in Figure 3.6). The transducers 
are housed in a plastic material for protection and isolation. In order to minimize the loss 
of ultrasound energy through the reverberator, ultrasound gel is applied at the 
transducer-reverberator interface. This enhances ultrasound coupling and minimizes the 
energy losses.  
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Figure 3.7: A low-impedance multi-channel power amplifier circuit. 
 
As shown in the schematic above in Figure 3.4, the transducers and the TRA 
electronics are then connected to a multi-channel, low-impedance power amplifier 
circuit (shown in Figure 3.7). There are 16 power MOSFETs per channel. Each channel 
is controlled by the TRA electronics to deliver ultrasound either continuously or in a 
pulsed fashion, at the required frequency and duty cycle for a given period of time. The 
amplifier is powered by two +/- 30V 10 Amp power supplies that control the power to the 
external transducers and one 8V, 2 Amp power supply that enables the fans, integrated 
circuits and the general amplifier. The BNC input of the amplifier accepts 2 to 5 volt 
transistor-transistor logic signals supplied by the TRA electronic unit and amplifies the 
signal up to a maximum of +/− 30 volt push-pull square wave drive signal. The output of 
each amplifier channel is connected to an ultra-flexible coax cable terminated with a 
female BNC connector [73]. 
 
37 
 
After supplying all components with appropriate power sources and ensuring that all the 
connections are made properly the system is turned on.  The DC power source is set to 
at a constant voltage of 8V and the alternate power source is set to operate around 
24V.  
 
The parameter file located on the computing interface controls various acoustic 
parameters associated with the TRA electronics. The initial sweep i.e. a library of initial 
ultrasound pulses, the sensitivity value, duty cycle, time of operation are initialized as 20 
KHz-1MHz, 1.0126e-6 V/Pa 92%, 180000s respectively with a pulsed mode of 
operation. 
An initial wave signal (a transistor-transistor logic excitation signal from the range of 
ultrasound pulses) is applied to a transducer connected to the TRA channel through the 
TRA electronics. The signal then passes through the reverberating medium and is 
detected by the beacon. The piezo electric transducer of the beacon which is located at 
the center of the blood clot receives the initial signal and provides an electro-magnetic 
feedback to the TRA electronics. The TRA electronics receives this signal; time 
reverses the signal and stores the time-reversed signal. This step is subsequently 
repeated for each of the transducers connected to the different channels of the amplifier 
circuit. After having received signals from each of the transducers, time-reversing them 
and storing the time-reversed signals, simultaneous time-reversed signals 
(synchronized with the initial signal) from all the transducers are emitted at once. This 
generates an enhanced time-reversed signal that is directed towards the piezo electric 
transducer element of the beacon transducer located at the center of the clot [71, 72, 
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73]. From the set of signals that generate enhanced time reversed signals the one 
generating the best signal to noise ratio is selected for thrombolysis by the TRA 
electronics.  
The TRA system uses a graphical user interface that is based on a Matlab® program 
working in conjunction with the TRA electronics. The TRA electronics communicates 
with the PC through a 2 channel USB2 interface and is capable of operation with up to 
95% duty cycle [73].  The user initiates the MatLab® command window using the 
function call to the main program TRA_UI (`expert'). This function initializes the entire 
TRA system. Once initialized, the GUI enables the selection of frequency, pulse 
duration, pulse repetition, duty factor for the duration of the experiment in real time [73]. 
In our study we have already fixed these parameters within the parameter file instead of 
using the GUI.  
After thrombolysis the clot is removed and its mass is measured according to equation 
(1). The loss in clot mass is measured for three groups 1. Controls clots where no 
ultrasound was applied 2. Clots with 100U/ml thrombin added 3. Clots with no thrombin 
added. 
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3.4 Ultrasound focusing in large animals using Time Reversal Acoustics 
 
To investigate the ability to localize/focus ultrasound using time reversal acoustics in 
large animals, TRA based ultrasound focusing was carried in a 45lb cadaveric equine 
head. A 2cm by 2cm hole was drilled into the cadaveric skull between the forelock and 
the poll region exposing the dura mater.  
Four different experimental modalities were considered to demonstrate the focusing of 
ultrasound 
1. Beacon transducer and 1MHz reverberator  
Using a schematic similar to Figure 3.4 the beacon transducer is placed inside 
the equine brain as shown in Figure 3.8. A metal reverberator housing 1MHz 
PZT-4 piezoelectric crystals is placed in contact with the equine brain as shown 
in the Figure 3.8. To ensure ease of insertion for the catheters a metal bore was 
used to create a cylinder column within the equine brain. The column was then 
filled with saline to ensure a proper coupling between the reverberator and the 
beacon transducer. The beacon was inserted with a 5 French (Fr) introducer 
sheath at an insertion distance of 5 cm. The reverberator was placed at the 
medial part of the equine forehead and coupled with ultrasound gel. Ultrasound 
was delivered using this modality and subsequent focusing results were 
observed. 
.  
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Figure 3.8: Using 1 MHz reverberator and ultrasound “beacon” transducer to focus ultrasound energy within 
a horse brain.  
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Figure 3.9: (Left to Right) Focusing ultrasound energy in a horse brain using (Left) Hydrophone infusion 
catheter smart needle and 1 MHz reverberator (Middle) 190 KHz transducers and ultrasound “beacon” 
transducer (Right) 190 KHz transducers and multiple ultrasound “beacons”. 
 
2. Hydrophone infusion catheter smart needle and 1 MHz reverberator   
Using the experimental setup described in case 1, the beacon transducer is 
replaced with a hydrophone infusion catheter smart needle. To ensure proper 
coupling, the insertion site of the needle was supersaturated with saline. 
Ultrasound was delivered using this modality and subsequent focusing results 
were observed. The corresponding setup can be seen in Figure 3.9 (Left) 
 
3.  Beacon transducer and 190 KHz ultrasound  transducers  
Using the same experimental setup as described previously in case 1, the 1MHz 
reverberator is replaced with a set of 9 piezo electric ceramic ring transducers 
with resonant frequency of 190+/- 5 KHz (SMR 2809t60118, STEMiNC- Steiner 
and Martins, Inc.). Subsequently ultrasound energy was delivered to observe the 
corresponding focusing results. The corresponding setup can be seen in Figure 
3.9 (Middle).       
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4.  Multiple beacon transducers  and 190 KHz ultrasound  transducers 
This experimental modality used the same setup described in case 1. However 
two beacon transducers were used instead of one to focus ultrasound. The 
corresponding setup can be seen in Figure 3.9 (Right).  
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Chapter 4 
4. Results 
4.1 Focusing Experiments in cylindrical reverberator 
 
To investigate if ultrasound at low frequencies can be localized to a specific location, the 
initial sweep was limited to a range between 20 KHz-1.5 MHz. Enhanced time-reversed 
acoustic signals were obtained at 180 KHz, 342 KHz, 720 KHz and 1 MHz. Amongst 
these the frequencies focusing ultrasound at 342 KHz resulted in a signal with the 
highest signal to noise ratio (Figure 4.1). Choosing 342 KHz as the operating frequency 
TRA enhanced thrombolysis was performed.    
 
 
 
Figure 4.1: A highly enhanced time-reversed ultrasound signal at a frequency of 342 KHz (Left); Continuous 
burst of these ultrasound signals at 342 KHz for thrombolysing the clot in the cylindrical reverberator (Right); 
X-axis represents time in microseconds with the origin at the centre of X-axis. Y-axis represents peak-peak to 
pressure amplitude in kilo pascal (kPa) with origin at the centre of the Y-axis. 
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4.2 Thrombolysis 
 
 
 
Figure 4.2: Loss in clot mass when exposed to TRA enhanced ultrasound and loss in clot mass when not 
exposed to ultrasound in a) Clots where thrombin was added b) thrombin was not added. 
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Figure 4.3: Showing change in size of a blood clot pre and post thrombolytic treatment focusing ultrasound 
using Time Reversal Acoustics. (Left) Blood clot post treatment which is approximately 0.6-0.7 cm in 
diameter and 2 cm in length (Right) Blood clot pre-treatment which is of approximately 1-1.2 cm in diameter 
and 4.8 cm in length. 
 
 
The clots in the cylindrical reverberator were exposed to time-reversed ultrasound 
signals at 342 KHz (spherical focal volume of 4.59e-8 m3) for a period of 1800 seconds. 
The duty cycle of treatment was set at 92%. The peak-peak pressure varied from 
28KPa-45KPa per transducer. The intensity varied from 5.5mW/cm2 to 8mW/cm2. The 
clots (N=7) that were exposed to this ultrasound exhibited a mass loss of approximately 
63.23% (p <0.00005 with respect to controls). The control clots which were placed 
under similar conditions but not exposed to any ultrasound had a mass loss of 26.33%. 
Using the same acoustic parameters clots (N=5) with additional thrombin (100 U/ml) 
were exposed to ultrasound.  These set of clots had a loss of mass of 54.85% 
(p<0.0014 with respect to controls). The corresponding mass loss for control clots was 
29.81% (Figure 4.2). Figure 4.3 shows a change in the size of a blood clot pre treatment 
and post treatment. 
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4.3 Focusing experiments in equine head 
 
 
Figure 4.4: A highly enhanced time reversed signal obtained at 191 KHz and 342 KHz using 190 KHz external 
transducers and ultrasound ‘beacon’ transducer. 
 
 
Figure 4.5: A time-reversed signal focused at a location in the equine head using hydrophone infusion 
catheter smart needle and 1 MHz reverberator. 
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Figure 4.6: Time reversed signal obtained using hydrophone infusion catheter smart needle and 1 MHz 
reverberator. 
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Figure 4.7: Time reversed signal obtained using two beacon transducers and 190 KHz transducers. 
 
Using the four different experimental setups described in the methods we investigated if 
TRA based ultrasound could be localized within large animals and if an enhanced time-
reversed signal can be obtained which is comparable to the one used in an in vitro 
setting. The experimental setup which used the ultrasound ‘beacon’ transducer with 190 
KHz transducers gave (Figure 4.4) highly focused time reversed signals at 191 KHz and 
342 KHz respectively. The experimental setting (Figure 4.7) wherein two ultrasound 
beacons are inserted  in the equine brain surrounded by 190 KHz external transducers 
also resulted in a focused ultrasound signal. However the peak-peak amplitude was 
noticeably smaller when compared to the case where only one beacon transducer was 
used. The other two cases which involved the hydrophone infusion catheter smart 
needle (Figures 4.5 and 4.6) resulted in focused signals with high signal to noise ratios. 
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Chapter 5  
5. Discussion 
 
Ultrasound based thrombolysis over the years has evolved to play a more prominent 
role in Deep Vein Thrombosis. However there are still several challenges associated 
with this treatment methodology. Invasive ultrasound treatments are limited by the size 
of transducer which is dependent on the size of vessel. This in turn places a limitation 
on the frequencies and energy delivered thereby reducing the effectiveness of 
treatment. Transcutaneous ultrasound lacks the ability to deliver focused energy at a 
specific location [41]. This greatly reduces its effectiveness to deliver any therapeutic 
ultrasound or to enhance drug delivery.  Therapeutic ultrasound (0.7 MHz to 5 MHz) 
generally has relied on delivering high intensity ultrasound energy at the treatment 
location. High intensity focused ultrasound (HIFU) achieves the desired effect through 
thermal heating with temperatures upto 60oC [77]. This is not desirable with respect to 
DVT as there is a chance of damaging the tissues that lie between the transducers and 
the clots due to thermal heating [79]. Also the small size of vessels limits placed a 
limitation on delivering focused high intensity ultrasound energy without any thermal 
dissipation to neighboring tissue. The system we have presented has tried to overcome 
the above limitations by using a minimally invasive system that delivers highly focused 
low intensity external ultrasound energy. The low intense ultrasound avoids the effect of 
hyperthermia that is seen in HIFU. 
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We investigated if ultrasound energy at a low frequency (<1.5 MHz) and low intensity 
(<0.5 W/cm2) could be focused at the desired location using time reversal acoustics. We 
successfully demonstrated that it is possible to do so in vitro and in large animals. We 
also showed that it is possible to focus ultrasound at low frequencies (191 KHz and 342 
KHz) in both the cases.  The study also showed that though a focused signal was 
obtained in both cases the intensity was lower in animal studies. This result can be 
explained by the attenuation of already low-intensity ultrasound by equine skull and 
other tissues. By increasing the number of ultrasound transducers and also by removing 
the design limitation on the low-impedance amplifier circuit (current design has 10 
channels and allows an operational voltage of only 30 V) it may be possible to generate 
an enhanced signal similar to those in vitro conditions. The focusing experiments within 
the equine head also demonstrated the remarkable ability of focusing ultrasound at a 
specific location using Time Reversal Acoustics.  
 
Thrombolysis using the above acoustic parameters (Frequency-342 KHz, Duty Cycle-
92%, Repetition rate -10) showed a significant loss in clot mass in both sets of clots, 
one where thrombin was added and the one without additional thrombin. Previous 
studies reported [42] no loss in clot mass when using ultrasound alone at low 
frequencies of 120 KHz and 1 MHz. We report for the first time a significant loss in clot 
mass when using TRA based ultrasound at 342 KHz without a thrombolytic drug. We 
hypothesize that cavitation and microstreaming could be the dominating mechanisms 
that cause this thrombolysis. We also hypothesize that at these frequencies there 
should be increased clot permeability leading to better penetration of thrombolytics into 
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the clot. Thus we could see a reduction in the dosage of anticoagulants and 
thrombolytics resulting from ultrasound aided thrombolysis and ultrasound aided 
penetration. For the given set of porcine clots we have also seen that the thrombolysis 
seemed to be a constant (about 55% for thrombin added clots and around 63% for clots 
with no thrombin). Given a near constant clot size and thrombin concentration within the 
clots it is possible that the extent of thrombolysis is also a constant. 
We also observed that clots with additional thrombin had a reduced loss in clot mass as 
compared to the ones where no thrombin was added (54.85% vs 63.29%). Previous 
studies have shown that ultrasonic energy causes thrombolysis by disrupting the fibrin 
matrix [4, 53, 54]. It has also been reported that the amount of thrombin affects the 
extent of cross linking in the fibrin matrix. Increase in thrombin concentration reportedly 
increased the fiber diameter in the fibrin network [24]. Thus it is expected that the 
thrombin group exhibit lesser loss in clot mass as compared to the no thrombin group 
when exposed to the same ultrasound energy. It is also expected that at these 
frequencies the time-reversed ultrasound plays the dual role of acting as a therapeutic 
agent and as an enhancer of fibrinolysis by promoting drug dissipation. Studies have 
already shown that [42, 73] thrombolysis is enhanced at certain frequencies in presence 
of a thrombolytic drug. Thus the additional therapeutic nature imparted to the ultrasound 
due to time-reversal acoustics would further enhance the thrombolysis.  In addition the 
low frequencies reduce the harmful bioeffects of ultrasound like heating, have deeper 
penetrating power, lower attenuation as compared to higher frequencies [40].  
The study is limited due to the in vitro nature of the experiment and the use of porcine 
blood clots. However it is expected that this treatment model would have an enhanced 
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effect in humans due to higher plasminogen (0.8-1.2 U/ml in humans) concentration as 
compared to pigs (0.08-0.5 U/ml in pigs) and also due to an actively recruiting thrombus 
[42]. Ultrasound could also increase clot permeability to plasminogen and other 
thrombolytic drugs. Thus loss of clot mass is expected to be higher in human beings. 
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